

**BIOGRAPHICAL SKETCH**

NAME Annick D. Van den Abbeele, MD		Chief, Department of Radiology, Dana-Farber Cancer Institute; Associate Professor of Radiology, Harvard Medical School	
EDUCATION/TRAINING			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
University of Louvain, Brussels, Belgium	BA	1974	Basic Sciences
University of Louvain, Brussels, Belgium	MD	1978	Medicine

**A. Positions and Honors****Positions and Employment**

1978-1979	Internship, University of Louvain, Hospital St. Luc, Brussels Belgium
1979-1982	Rotating residency in Pediatrics, University of Louvain, Hospital St. Luc, Brussels, Belgium
1981	Chief Resident, Hospital St. Luc, Brussels, Belgium
1992-1993	Rotating residency in Nuclear medicine and clinical fellowship in Radiology, Joint Program in Nuclear Medicine, Harvard Medical School (HMS), Boston, MA
1982-1984	Fellow in Neonatology, Vanderbilt University Medical Center, Nashville, TN
1984-1987	Fellow in Radiology and in Nuclear Medicine, HMS, Boston, MA
1987-1992	Associate in Radiology, Department of Radiology, Brigham and Women's Hospital (BWH), Boston, MA
1992-1993	Resident in Radiology (Nuclear Medicine), and Clinical Fellow in Radiology, BWH, HMS, Boston, MA
1993-present	Senior Radiologist, BWH and Dana-Farber Cancer Institute (DFCI), HMS, Boston, MA
1994-1995	Acting Director, Division of Nuclear Medicine, DFCI, HMS, Boston, MA
1995	Director, Division of Nuclear Medicine/PET, DFCI, HMS, Boston, MA
2004-2006	Clinical Director, Department of Radiology, DFCI, Boston, MA
2006-2007	Acting Chief, Department of Radiology, DFCI, Boston, MA
2007-	Chief, Department of Radiology, DFCI, Boston, MA
2007-	Founding Director, Center for Biomedical Imaging in Oncology, DFCI, Boston, MA

**Other Experience and Professional Memberships**

1993-1994	Committee on Biomedical Isotopes, Assistant to the Chairman, Institute of Medicine, National Academy of Sciences
1994-present	Chairperson, Radiation Safety Committee, Dana-Farber Cancer Institute
1995	Guideline Development Subcommittee, Member, Society of Nuclear Medicine
1998-present	Medical Advisor, Nuclear Medicine Technology Program, Massachusetts College of Pharmacy and Allied Health Sciences
1997, 2002-2001	Scientific Program Committee, Reviewer, Society of Nuclear Medicine NCI Progress Review Group. Sarcoma, Invited Participant
2001-present	Editorial board, Academy of Molecular Imaging Journal: Molecular Imaging and Biology
2001-2003	PET Center of Excellence Board of Directors, Society of Nuclear Medicine
2002-present	American College of Radiology Imaging Network (ACRIN) Nuclear Medicine/PET Committee, Member and P.I.
2002-present	Association of American Cancer Institutes Imaging Committee, Member
2003, 2006	National Comprehensive Cancer Network (NCCN), Clinical Practice Guidelines in Oncology: GIST Consensus Group. Invited Participant
2003	Institute for Clinical PET (ICP) Council of the Academy of Molecular Imaging, Member
2005	NCI workshop: The role of FDG-PET in the evaluation of therapeutic response in cancer, Discussion Leader

## Principal Investigator/Program Director

- 2006-present BWH/DFCI Radiology Advisory Cabinet and Executive Committee, Member
- 2007-present DFCI Advisory Cabinet and Medical Staff Executive Committee, Member
- 2007-present ACRIN Experimental Imaging Sciences Committee (EISC), Member
- 2007-present ACRIN Imaging Core Lab, Member
- 2007-present Imaging Response Assessment Teams (IRAT), Corresponding Institutional Member and Quantitative Imaging sub-committee Member
- 2007-present Clinical and Translational Science Center Innovations Executive Committee (IEC), Member, CTSA, Harvard Medical School
- 2007-present Chair, Partners Radiology Research

## Honors

- 1991 William F. Milton Fund, Harvard University
- 1991 Radiology Foundation, Harvard Medical School
- 1991 First Annual Research Award for Outstanding Contribution to Radiological Research by a Member of the Junior Faculty, Department of Radiology, the BWH and HMS
- 1998 Best Paper, New England Society of Plastic and Reconstruction Surgeons, Annual Meeting
- 2000 Third Annual Holman/Kaplan Memorial Lectureship, New England Chapter, Society of Nuclear Medicine
- 2001 DFCI Partners in Excellence: Nuclear Medicine Team Quality Improvement Award: Department of the Year
- 2003 Marie Curie Lecture, Massachusetts College of Pharmacy
- 2004 Tenth Annual William D. Kaplan Lecture, Brigham and Women's Hospital
- 2004 Ceremonial First Pitch at Tigers vs. Red Sox Game, in Celebration of the Jimmy Fund, 08/27/04
- 2006 Certificate of Merit Award: "Development of a Centralized Service for Standardized Tumor Measurements at a Multi-Institutional Collaborative Cancer Center--The Tumor imaging Metrics Core," RSNA
- 2007 Certificate of Merit Award: "Radiological Response and toxicity of the New Targeted Molecular Therapies for Cancer--What the Radiologist Needs to Know," American Roentgen Ray Society

## **B. Selected peer-reviewed publications (in chronological order)**

(Publications selected from 64 peer-reviewed publications)

1. Van den Abbeele AD, Treves ST, Lebowitz RL, Bauer S, Davis RT, Retik A, Kolodny A. Vesicoureteral reflux in asymptomatic siblings of patients with known reflux: radionuclide cystography. *Pediatrics* 1987;79:147-53.
2. Van den Abbeele AD, Hardoff R, Royal HD, Kolodny GM. Bone metastases in Zollinger-Ellison syndrome: detection by bone scintigraphy. *Clin Nucl Med* 1987;12:954-5.
3. Van den Abbeele AD, Aaronson RA, Adelstein SJ, Kassis AI. Does the in vitro testing of the immunoreactivity of an antibody reflect its in vivo behavior? *J Nucl Med Allied Sci* 1988;32:260-7.
4. Van den Abbeele AD, Aaronson RA, Taube RA, Adelstein SJ, Kassis AI. PreadSORption of radiolabeled monoclonal antibodies to liver and spleen tissues leads to higher tumor-to-normal-tissue ratios. *J Nucl Med Allied Sci* 1991;34:94-102.
5. Van den Abbeele AD, Aaronson RA, Daher S, Taube RA, Adelstein SJ, Kassis AI. Antigen-binding site protection during radiolabeling leads to a higher immunoreactive fraction. *J Nucl Med* 1991;32:116-22.
6. Adelstein SJ, Kassis AI, Baranowska-Kortylewicz D, Van den Abbeele AD, Mariani G, Ito S. Potential for tumor therapy with iodine-125 labeled immunoglobulins. *Int J. Rad Appl Instrum B*, 1991;18:43-44.
7. Van den Abbeele AD, Tutrone RF, Berman RM, Baranowska-Kortylewicz J, Barclay PD, Richie JP, Adelstein SJ, Kassis AI. Tumor-targeting potential of radioiodinated iododeoxyuridine in bladder cancer. *J Nucl Med* 1996;37:315-320.
8. Bartold SP, Donohoe KJ, Fletcher JW, Haynie TP, Henkin RE, Silberstein EB, Royal HD, Van den Abbeele AD. Procedure guideline for gallium scintigraphy in the evaluation of malignant disease. *J Nucl Med* 1997;38:990-994.
9. Kassis AI, Wen PY, Van den Abbeele AD, Baranowska-Kortylewicz J, Makrigiorgos M, Metz KR, Matala KC, Cook C, Sahu SK, Black P McL, Adelstein SJ. 5-[<sup>123</sup>I]Iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats. *J Nucl Med* 1998;39:1148-1154.
10. Slavin SA, Van den Abbeele AD, Losken A, Swartz MA, Jain RK. Return of lymphatic function after flap transfer for acute lymphedema. *Annals of Surgery*. *Ann Surg* 1999;229:421-427.
11. Friedberg JW, Van den Abbeele AD, Kehoe K, Singer S, Fletcher CD, Demetri GD. Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of patients. *Cancer* 1999;86:1621-1627.
12. Frohlich EC, Chen JL, Neuberg D, Kehoe KM, Van den Abbeele AD. When is hilar uptake of <sup>67</sup>Ga-citrate indicative of residual disease after CHOP chemotherapy? *J Nucl Med* 2000;41:269-274.

Principal Investigator/Program Director

13. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to Imatinib mesylate therapy in gastrointestinal stromal tumors (GIST). *European J of Cancer* 2002;S56-S62
14. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts P, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman S, Harmon D, Silberman S, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CDM, Joensuu H. Antitumor effects of an oral selective tyrosine kinase inhibitor, imatinib mesylate in patients with advanced gastrointestinal stromal tumors. *N Engl J Med* 2002;347:472-480
15. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Brunker BJ, Kiese B, Eisenberg MSc, Roberts PJ, Singer S, Fletcher CDM, Silberman S, Dimitrijevic S, Fletcher JA. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. *J. Clin. Oncol* 2003;21:4342-4349
16. Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Ng AK, Mauch PM, Canellos GP, Van den Abbeele AD. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with *de novo* Hodgkin Lymphoma: a blinded comparison. *Leukemia & Lymphoma* 2004;45:85-92
17. Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. *Clin Cancer Res* 2004;10:5732-5740
18. McCollum AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case MA, Posner MR, Van den Abbeele AD. Positron emission tomography with (18)F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. *Head and Neck* 2004; 60:890-896
19. Burrell SC, Van den Abbeele AD. 2-Deoxy-2-[F-18]fluoro-D-glucose-Positron Emission Tomography of the head and neck: An atlas of normal uptake and variants. *Molecular Imaging and Biology* 2005; 7:244-256
20. Ng AK, Bernardo MV, Silver B, Van den Abbeele AD, Stevenson MA, Fisher DC, Mauch PM. Mid- and post-ABVD Gallium Scanning Predicts for Recurrence in Early-Stage Hodgkin's Disease. *Int J Radiat Oncol Biol Phys* 2005; 61:175-84
21. Shankar S, vanSonnenberg E, Desai J, DiPiro PJ, Van den Abbeele A, Demetri GD. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. *Radiology* 2005; 235:892-898
22. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, Van den Abbeele A, Yap J, Sullivan D. Consensus recommendations for the use of <sup>18</sup>F-FDG PET as an indicator of therapeutic response in patients in national cancer institute trials. *J Nucl Med* 2006; 47:1059-1066
23. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J; NCCN Task Force report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)- Update of the NCCN Clinical Practice Guidelines. *J Natl Compr Canc Netw.* 2007;5 Suppl 2:S1-29; quiz S30
24. Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J, Morgan JA, Corless CL, George S, Tuncali K, Silverman SG, Van den Abbeele AD, van Sonnenberg E, Demetri G. Clonal evolution of resistance to imatinib in patients with metastatic GIST: Molecular and radiologic evaluation of new lesions. *Clin Cancer Res* 2007, 13:5398-5405
25. Sheehy N, Fennessy F, Van den Abbeele A D. The Utility of 18F-FDG-PET in the Diagnosis and Management of Colorectal Carcinoma. *Seminars in Colon and Rectal Surgery* 2007, 18(2):96-106.
26. Holdsworth CH, Badawi RD, Manola J, Kijewski MF, Israel DA, Demetri GD, Van den Abbeele AD. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. *AJR Am J Roentgenol* 2007, 189(6):W324-30.
27. Herbst, RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, de Vries DJ, Eberhard, DA, Lyons B, Lutzker SG, Johnson BE. Efficacy and safety of single agent Pertuzumab, a HER dimerization inhibitor, in patients with non-small cell lung cancer. *Clin Cancer Res* 2007: 13:6175-6181
28. El Fakhri G, Santos PA, Badawi RD, Holdsworth CH, Van den Abbeele AD, Kijewski MF. Impact of acquisition geometry, image processing, and patient size on lesion detection in whole-body 18F-FDG PET. *J Nucl Med* 2007, 48(12):1951-60
29. Chu TF, Rupnick MA, Kerkela R, Dallabrida, SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai j, George S, Morgan JA, Harris D, Ismail NS, Chen JH, Shoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH. Cardiotoxicity Associated with the Tyrosine Kinase Inhibitor Sunitinib. *Lancet* 2007, 370:2011-19
30. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. *J Clin Oncol* 2008, 26:1993-1999

Principal Investigator/Program Director

31. Hodi SF, Friedlander P, Corless C, Heinrich M, MacRae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquea E, Demetri G, Fisher D. A Major Response to Imatinib Mesylate in KIT Mutated Melanoma. *J Clin Oncol* 2008, 26:2046-2051
32. Van den Abbeele, AD. Abdomen: The Lessons of GIST—PET and PET/CT. *The Oncologist* 2008,13 Suppl 2, 8-13
33. Masciari S, Van den Abbeele AD, Diller LR, Rastarhuyeva I, Yap J, Schneider K, Digianni L, Li FP, Fraumeni JF, Jr., Syngal S, Garber JE. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. *JAMA* 2008 299:1315-1319
34. Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, Treister N, Hideshima T, Sheehy N, Chhetri S, Connell B, Xie W, Tai YT, Szot-Barnes A, Tian M, Schlossman RL, Weller E, Munshi NC, Van Den Abbeele AD, and Anderson KC. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. *Clin Cancer Res* 2008, 14:2387-2395
35. Friedberg J, Jacobsen E, Neuberg D, Kutok J, Munoz O, Boussiotis V, Reynolds H, Fisher D, Szot A, Van Den Abbeele A, Freedman A. Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept. *Leuk Lymphoma*. 2008 May;49(5):902-9.
36. Ertuk M, Van den Abbeele AD. Role of PET/CT Scanning in Initial and Post-Treatment Assessment of HD. *JNCCN* 2008 Jul;6(6):623-32.
37. Sheehy N, Kulke MH, Van den Abbeele AD. F-18 FDG PET/CT in the diagnosis and management of a pericardiac paraganglioma. *Clin Nucl Med*. 2008 Aug;33(8):545-6.

**C. Research Support**

**Ongoing Research Support**

ACTIVE

5P30 CA006516-41 (Benz) 11/01/05 - 9/30/10  
NCI

Dana-Farber Harvard Cancer Care (DFHCC) Comprehensive Cancer Center Grant (Tumor Imaging Metrics Core)  
Goal: To provide standardized reproducible longitudinal measurements on CT, MRI, and PET/CT scans performed on patients enrolled in clinical trials within DFHCC through an imaging core: the Tumor Imaging Metrics Core.  
Role: Tumor Imaging Metrics Core co-PI: Van den Abbeele, Barish, and Harris (Core PIs)

UL1 RR025758-01 (Nadler) 05/19/08-04/30/13  
NIH/NCRR

Harvard Clinical and Translational Science Center  
The Harvard CTSC is a new collaborative and trans-disciplinary environment to foster clinical translational research and training for Harvard and its affiliated Academic Healthcare Centers  
Role: Site Director of Translational Imaging Consortium